A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers.
Adult
Aerosols
/ administration & dosage
Aged
Antineoplastic Agents
/ administration & dosage
Female
Gastrointestinal Neoplasms
/ drug therapy
Humans
Infusions, Parenteral
/ methods
Laparoscopy
/ methods
Male
Maximum Tolerated Dose
Middle Aged
Organoplatinum Compounds
/ administration & dosage
Oxaliplatin
/ administration & dosage
Peritoneal Neoplasms
/ drug therapy
Peritoneum
/ metabolism
Gastrointestinal carcinoma
Oxaliplatin
PIPAC
Peritoneal carcinomatosis
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
28
02
2020
revised:
28
08
2020
accepted:
02
09
2020
pubmed:
12
10
2020
medline:
23
2
2021
entrez:
11
10
2020
Statut:
ppublish
Résumé
The objectives were to define the maximum tolerated dose (MTD), safety profile and pharmacokinetics (PKs) of intraperitoneal oxaliplatin delivered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with advanced peritoneal carcinomatosis from gastrointestinal tract cancers. PIPAC was applied every 4-6 weeks, for 5 cycles, in a phase I dose-escalation study using a 3 + 3 design. The first dose level was 90 mg/m Ten patients with 33 PIPAC sessions were included. No dose limiting toxicity (DLT) occurred at 90 mg/m The MTD of oxaliplatin during PIPAC is 90 mg/m
Identifiants
pubmed: 33039812
pii: S0959-8049(20)30492-5
doi: 10.1016/j.ejca.2020.09.010
pii:
doi:
Substances chimiques
Aerosols
0
Antineoplastic Agents
0
Organoplatinum Compounds
0
Oxaliplatin
04ZR38536J
Banques de données
ClinicalTrials.gov
['NCT03294252']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-44Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement O.G. received honoraria from Gamida. The others authors have no interest conflict to declare.